Toumaz : £32.3 million acquisition of Frontier Silicon

Acquires Frontier Silicon on 08.22.2012Toumaz Limited has closed on its acquisition of chip-maker Frontier Silicon.The price of the previously-announced deal was not disclosed.The companies say there’s an alignment of Toumaz’ healthcare, radio and wireless chip technologies and Frontier Silicon’s expertise in semiconductor, module and software systems.Frontier supplies digital audio chips and modules to consumer electronics brands and specializes in Internet-connected and streaming audio. Frontier has R&D centers in the U.K., Hong Kong and China; its customers include Bose, Bang and Olufsen, Pure, Philips, Sony, Panasonic, SiriusXM and Yamaha.The merged U.K.-based entities say they will be able to address high growth markets, specifically healthcare, consumer sport and fitness, digital radio and network audio with wireless semiconductors.The new, merged entity has shipped 17 million digital radio chipsets to date, according to Toumaz, which predicts the market will expand as new areas adopt digital radio.

TOUMAZ EYES FITNESS BOOM VIA £32M FRONTIER SWOOP Monday, 20 August 2012 17:23   Toumaz, a transatlantic pioneer of ultra-low power wireless communications technology has identified massive global opportunities in the fitness and healthcare markets after completing the £32.3 million acquisition of Frontier Silicon in Cambridge UK. The deal completes a neat piece of symmetry for Toumaz CEO Anthony Sethill, who was formerly founder and CEO of Frontier but left in December. Frontier is a market-leading supplier of digital audio chips and modules to global consumer electronic brands, and a leader in internet-connected and streaming audio. It brings important electronic engineering resource to the Group with R & D centres in the UK, Hong Kong and China and a strong customer support focus. Frontier’s customers include Bose, Bang and Olufsen, Pure, Philips, Sony, Panasonic, Sirius XM and Yamaha. There is a strong technological alignment of Toumaz’s healthcare, radio and wireless chip technologies and Frontier’s expertise in semiconductor, module and software systems, which will be integrated to create a genuine total solution provider. Toumaz also has the opportunity to exploit Frontier’s established commercial infrastructure and sales and marketing expertise. The enlarged group will be capable of addressing key high growth markets, specifically professional healthcare, consumer sport and fitness, digital radio and network audio. The Group’s silicon and software roadmap will deliver key solutions for each of its target markets. Sethill said: “Bringing these two innovative UK technology companies together is a very exciting event. Toumaz’s wireless solutions have huge potential and combined with the software systems, commercial expertise and customer access of Frontier, we will create a leading provider of wireless semi-conductor solutions. “These target the healthcare, sport and fitness and consumer electronics sectors, together with our strategic technology partner and shareholder, Imagination Technologies PLC. “The new enlarged group is already the global leader in digital radio solutions, having shipped over 17 million chip sets to date. This market will continue to expand as more territories adopt digital radio and will be further enhanced by the availability of new lower cost, higher performance chipsets, making digital radio more accessible. “Our professional healthcare offering continues to be a key focus for the group with clear market needs to be addressed. Up to 87 per cent of hospitals in the US have stated an interest in installing wireless monitoring technology in the next two to five years and our healthcare product aims to be a key driver in the evolution of healthcare monitoring. The Toumaz ‘Sensium Vitals’ monitoring solution has FDA approval and will shortly start pilots in the US. “By 2016, the global market for wireless sports and fitness monitoring devices is forecast at 120m units and the opportunity to leverage our healthcare capabilities into the consumer arena is significant.” 

啟通科技: 無線電子紙尿布 !!

亞洲銀髮族 企業新商機 財經新聞組 綜合報導 August 23, 2012 06:00 AM亞洲人口迅速老化，雖然為政府和社會帶來挑戰，但也給企業帶來新商機，針對高齡人口及其照護者提供服務的產業尤其前景可期。 華爾街日報報導，未來數十年，亞太地區人口結構可能出現重大改變。聯合國亞太經濟社會委員會(UNESCAP)預估，亞太地區60歲以上人口將在2050年前成長兩倍，至超過12億，也就是每四人當中就有一名老人。亞洲各行各業的大公司競相為高齡人士推出新產品和服務，醫療保健相關業者更準備迎接需求激增的榮景，安養中心是成長最快的領域之一。在日本，原與高齡化問題沾不上邊的企業也想分一杯羹。和民公司原本經營日式居酒屋，但在2005年兼開安養中心，且後者的營業利潤已在上年度超過居酒屋。日本人口高齡化程度居全球之冠，近30%的日本人已滿60歲。台灣、香港、中國大陸、南韓和新加坡等亞洲其他地區的高齡人口比也可望激增。例如，中國60歲以上人口現占全國的13.3%，高於2000年的10.3%，且增速可能加快。但據新華社報導，相較於高齡人口，中國安養中心的護士和床位都不足。亞洲最大醫院營運商馬來西亞綜合保健控股公司(IHH)上月在星、馬上市，掛牌首日的股價表現十分亮麗。分析師說，全球高齡化趨勢使IHH成為長期投資的好選擇。部分科技創業家看準機會，已開始開發能銷售給醫療保健業者的產品和服務。來自中國廣州的工程師黃新凱開發出拋棄式成人電子紙尿布，配備濕度感應器，可透過無線監測系統，以個人電腦和手機對安養中心工作人員發送警示。現年50歲的王凱文在香港創立啟通科技，並開始銷售這種特別的紙尿布。每片售價不到1.2美元，但安養中心須購買或租用無線監測系統。香港有五家安養中心正在測試這種尿布，啟通的台灣代理商則已收到10萬片尿布的訂單。在東京也設立辦事處的啟通預估，截至明年3月底的本年度營收可達約100萬美元。

盛弘…天津 託管醫院業務!!!

盛弘登「陸」，擬收購博輝25%股權，有機會跨足蛋白質新藥 財訊快報 (2012-08-22 17:10) 分享| 自體脂肪豐頰40000,自體脂肪豐頰安全維持時間五年以上,抽脂溶脂一區2萬! 【財訊快報／何美如報導】盛弘醫藥( 8403 )成功登「陸」，與大陸地產醫療集團合作於天津的長期照護已正式營運，也持續與華北、華中等其他集團洽談合作，也洽談醫院管理的業務。另外，盛弘跨入昨公告，將斥資2500萬元認購博輝生技股票，預計將持有25%股權，未來更有機會跨入蛋白質新藥領域，為營運添想像空間。該公司表示，目前持續將轉投資公司通路、業務與盛弘醫藥既有資源整合，未來效益將逐漸顯現。持股69.74%的濾材子公司敏成，目前資本額2.53億元，去年8月30日登錄興櫃，去年每股稅後盈餘1.45元，預計明年申請上櫃。另一家瑪科隆，目前在國內通路包括2,378家診所、1,364家藥局，規劃明年公發並登錄興櫃。盛弘昨日公告，將以每股面額新台幣10元認購博輝生技股權，總投資金額為新台幣25,000仟元，共計2,500仟股，將持有25%股權。博輝生技為一從事血漿製劑研發及生產製造之公司，具純化蛋白質相關業務，法人預期，有機會跨入蛋白質新藥領域，為營運添想像空間。盛弘成功進軍中國大陸，該公司表示，大陸地產醫療集團合作的長期照護，近日在天津正式營運，盛弘主要是進行委任託管，目前持續與其他集團洽談合作，先鎖定華北、華南地區，也洽談醫院管理的業務，下半年可望有好消息。

Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline

August 21, 2012 | By John Carroll Allergan isn't just about pretty faces. The maker of Botox also has some deep pockets and a serious scientific ambition. Building on a $420 million deal it already has in place with Switzerland's Molecular Partners, the pharma company ($AGN) has come back to the bargaining table to deepen its pipeline for ophthalmic drugs. Allergan paid $62.5 million upfront and promised up to $1.4 billion dollars in milestones in the deal, which covers a pair of R&D programs. In one pact Allergan is licensing rights to MPO260, an anti-VEGF-A/PDGF-B treatment for wet, age-related macular degeneration. The two companies will push the program through human proof-of-concept, at which point the Swiss biotech will have the option to co-fund further development in exchange for a big step-up in royalties. The second stage of the agreement covers the discovery of new eye drugs, with Allergan holding on to three options for exclusive licensing rights. Allergan first stepped up to team up with Molecular Partners back in the spring of 2011, lured by the Swiss company's DARPin technology. Allergan paid $45 million upfront to collaborate on a Phase IIb study of MP0112, a DARPin protein targeting VEGF under investigation for the treatment of retinal diseases. With another $375 million in milestones, Allergan is now committed to a total of $1.9 billion in cash and biobucks.

紅電醫 董事長兼任執行長

 【廣編】兩人生活不應該如此枯燥發言時間 101/08/2317:07:02發言人 謝治緯 發言人職稱 總經理 發言人電話 (03)666-9596 主旨 公告本公司董事會決議由本公司董事長兼任執行長符合條款第6款事實發生日101/08/23說明 1.董事會決議日期或發生變動日期:101/08/232.舊任者姓名及簡歷:不適用3.新任者姓名及簡歷:陳敏鏞 紅電醫學科技股份有限公司董事長4.異動情形（請輸入「辭職」、「職務調整」、「解任」、「任期屆滿」或「新任」）:新任5.異動原因:考量業務需要增設執行長一職，並經董事會決議由本公司董事長兼任。6.新任生效日期:101/08/237.其他應敘明事項:無以上資料均由各公司依發言當時所屬市場別之規定申報後，由本系統對外公佈，資料如有虛偽不實，均由該公司負責.